The rHA 20% product, derived from yeast, is a highly purified alternative to human serum albumin, matching it structurally ...
Shilpa Medicare Ltd announces that the results of its Phase I clinical trials were accepted by Subject Expert Committee ...
Shilpa Medicare's Recombinant Human Albumin 20% (rHA) is derived from yeast and offers a highly purified, structurally and ...
Shilpa Medicare has informed that the subject expert committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval ...
In relation to the successful completion of Phase I clinical trials, Shilpa Medicare Ltd has announced that the Subject ...
Campus Chemical Instrument Center, Mass Spectrometry & Proteomics Facility, The Ohio State University, Columbus, USA ...
was an acute shortage of human albumin. “This vital supplement”, he explained, “is crucial for patients with low blood volume, inadequate albumin production, or those recovering from major ...
Purpose: The technical issues surrounding the use of albumin in parenteral nutrient (PN) solutions are reviewed. Summary: Five criteria have been suggested to determine which compounds are optimal ...
A paper published in Gravitational and Space Research unveils insights gained from International Space Station ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback